Ned Biosystems
Biotechnology, 245 1st St, Cambridge, Massachusetts, 02142, United States, 1-10 Employees
Phone Number: +19*********
Who is NED BIOSYSTEMS
Founded to allow patients to achieve and sustain No Evidence of Disease NED BiosystemsTM was founded to develop safe, efficacious, and comprehensive systems treatments for complex disease...
Read More
- Headquarters: 245 1st St, Cambridge, Massachusetts, 02142, United States
- Date Founded: 2008
- Employees: 1-10
- Revenue: $5 Million to $10 Million
- Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8071
Does something look wrong? Fix it. | View contact records from NED BIOSYSTEMS
NED Biosystems Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding NED Biosystems
Answer: NED Biosystems's headquarters are located at 245 1st St, Cambridge, Massachusetts, 02142, United States
Answer: NED Biosystems's phone number is +19*********
Answer: NED Biosystems's official website is https://nedbiosystems.com
Answer: NED Biosystems's revenue is $5 Million to $10 Million
Answer: NED Biosystems's SIC: 8071
Answer: NED Biosystems has 1-10 employees
Answer: NED Biosystems is in Biotechnology
Answer: NED Biosystems contact info: Phone number: +19********* Website: https://nedbiosystems.com
Answer: Founded to allow patients to achieve and sustain No Evidence of Disease NED BiosystemsTM was founded to develop safe, efficacious, and comprehensive systems treatments for complex disease, beginning with the development of the patented NED-170 for treatment of cancer. A systems-based approach to treat disease comprehensively targets the behavior of the entire biological system instead of a single component. We begin with a focus on patients and their families. NED seeks to dramatically improve patients outcomes with treatments that lack the toxicity and side effects of todays treatments, allowing patients a high quality of life. NED-170 takes a systems approach that combines repurposed, oral agents well-documented in humans to affect critical cancer disease-driver processes at doses that lack customary toxicity and side effects. 50%-80% of all cancer patients have no genetically sequenced matched therapy options. NED-170 is designed to initially treat these patients. When the pandemic hit NED deployed its systems methodology to develop NED-260 to be a universal antiviral treatment for existing infectious diseases and those not yet known. NED-260 is designed to protect multiple pathways within patients cells from attack by a broad range of viruses. NED-260s treatment goal is to act early in the infection process to minimize, or eliminate, the advancement to severe disease, ideally allowing many patients to recover at home.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month